Manufacturing.Net November 23, 2009

WASHINGTON (Kyodo) — British drug maker GlaxoSmithKline Plc. is suspending the use of 170,000 doses of its new H1N1 influenza vaccine in Canada given a higher-than-usual rate of reported side effects, Canadian media reported Monday.

Japan’s Health, Labor and Welfare Ministry, which has a contract with the pharmaceutical firm to buy […]